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Defined key terms: 
-Antiviral: An agent that kills a virus or that suppresses its ability to replicate and, 
hence, inhibits its capability to multiply and reproduce. 
-Method validation: The process of verifying that a method is fit for purpose.  
-Selectivity: Selectivity is the ability of the bioanalytical method to measure and 
differentiate the analytes of interest and internal standard in the presence of 
components which may be expected to be present in the sample. 
-Precision: The precision of an analytical procedure expresses the closeness of 
agreement (degree of scatter) between a series of measurements obtained under the 
stipulated conditions. 
-Accuracy: The accuracy of an analytical procedure expresses the closeness of the 
determined value to the value which is accepted either as a conventional true value or 
an accepted reference value.  
-Robustness: Robustness is a measure of its capacity to remain unaffected by small, but 
deliberate variations in method parameters and provides an indication of its reliability 
during normal usage. 
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Abstract 
Background: IFN-α5 has demonstrated that induces stronger signaling and higher 
expression of antiviral genes than IFN-α2, the current treatment in chronic viral 
hepatitis. However, there is no specific and validated quantification method in order to 
conduct kinetic studies as part of the preclinical and clinical evaluation for regulatory 
purposes.  
Results: A novel integration of an antiviral assay against the cytopathic effect of the 
encephalomyocarditis virus in HeLa cells with a very sensitive method for assay 
processing, Vialight® Plus assay, is presented for IFN-α5 activity quantification. The 
bioassay has been validated in macaque and human serum and it has demonstrated to be 
selective, precise and accurate.  
Conclusion: The validated bioassay meets suitable acceptance criteria for these types of 
biological assays.  
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Introduction 
Interferons (IFNs) are the first line of defense against viral infections in mammals. In 
addition to their antiviral activity, they have also shown several antiproliferative and 
immunomodulatory effects [1].  Human type I IFNs includes a multigene family of 
different IFN-α subtypes (13 subtypes) and a single IFN-β. The IFN-α subtypes are very 
similar at the structural level and all of them interact with the same receptor, but 
differences have been found in their biological activity [2].   
Hepatitis C virus (HCV) infection is notably by the tendency to develop chronicity, 
being the main cause of hepatic disease. 130 million people are chronically infected by 
the virus, which resembles that the virus has developed mechanisms particularly 
efficient to avoid the antiviral system. Six main genotypes (1-6) distinguish the global 
geographic diversity of HCV and a multitude of closely related subtypes (a-j) within 
these genotypes are also defined and may influence clinical outcome and treatment 
options [3]. Current treatment consists in the combined administration of pegylated 
IFN-α2 and Rivabirin. Although main of the patients infected with genotype 2 or 3 
show a sustained virological response (SVR) to the current standard of care, only 50% 
of those infected with genotype 1 achieve SVR with this therapeutic strategy. As more 
than 80% HCV infected patients in Western world and Asia correspond to genotype 1, 
an increase in the efficacy of IFN-α treatment is urgently needed. 
IFN-α5 has been found to be the main IFN-α subtype expressed in liver of healthy 
people and is markedly decreased in the livers of patients with chronic HCV infection 
as compared with patients with other liver diseases (including hepatitis B virus chronic 
infection) [4]. It has also been demonstrated that it induces stronger signaling and higher 
expression of antiviral genes than IFN-α2 [5]. This data suggests that exogenous 
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administration of IFN-α5 to HCV chronically infected patients might be very useful for 
the effective virus clearance over the current use of IFN-α2. These findings warrant 
preclinical studies in order to evaluate its safety and efficacy in animal models, and its 
subsequent clinical development.  
In order to conduct successful preclinical and clinical studies for regulatory purposes, 
IFN-α5 has to be quantified in biological fluids in order to obtain pharmacokinetic and 
toxicokinetic data to support and interpret the pharmacological and toxicological 
findings. Moreover, the quality of these pharmacokinetic and toxicokinetic studies is 
directly related to the quality of the underlying bioanalytical data; so, the validation of 
the bioanalytical method is a critical requirement [6].  
IFN-α5 is a very active substance, so the dose administered to animals or humans is 
very low, leading to very low concentration levels in biological samples. The 
aforementioned, together with the fact that low volumes of biological samples could be 
extracted at each time in pharmacokinetic studies so as to avoid altering the individual 
volemia, explains the need to use very sensitive analytical methods in the determination 
of IFN-α5. Attempts of our research group to quantify it using chromatographic 
methods (HPLC, LC-MS, etc.) have not given good results regarding sensitivity. In 
addition, there are no ligand-binding assays capable of specifically detecting IFN-α5 
because there are no IFN-α5-specific antibodies. Therefore, the idea of quantifying IFN-
α5 through its antiviral activity by means of an antiviral assay (AVA) arose. 
Historically, antiviral assays have been the first type of biological assays developed for 
the quantification of IFN activity, but no validation data has been reported for any of 
them. Some combinations of suitable cell lines with viruses have demonstrated to be 
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highly sensitive, although they showed considerable inter-assay variations, mostly 
because of the staining and fixing procedures needed to end the AVA.  
Due to the aforementioned, the aim of this study was to develop a very reproducible, 
sensitive and rapid method in order to provide robust dose-response data for IFN-α5 
activity. For this purpose, an AVA, with the combination of the HeLa cell line and the 
encephalomyocarditis virus (EMCV), has been integrated for the first time with the  
Vialight® Plus assay. This method has been validated, under GLP conditions, in order to 
quantify IFN-α5 activity in macaque (Macaca fascicularis) and human serum. Human 
serum has been chosen due to the fact that it will be the main matrix in clinical studies. The 
macaque was chosen because it is the most adequate animal model for the preclinical 
evaluation of IFN-α5, given the fact that it is an interferon of human origin and that its 
pharmacological activity and interaction with the receptor is known to be species-
specific [7].   
Therefore, the novelty of this study consists on the integration for the first time of an AVA 
with EMCV in HeLa cells, with Vialight® Plus assay for processing of AVA, and on its 
validation under GLP conditions to a level which ensures precise and accurate 
measurements of IFN-α5 activity in serum samples. All the expected criteria for these most 
widely available biological assays for IFNs have been achieved. 
 
Materials and methods 
Reagents 
Dulbecco´s Modified Eagle´s Medium (DMEM) + GlutaMAX™ ([+] 4.5 g/L glucose, [-] 
pyruvate), PBS with and without Ca2+/Mg2+ and fetal bovine serum were purchased 
from Gibco; Penicilin-Streptomycin, Tripsin/EDTA and Vialight® Plus kit from Lonza; 
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trypan blue dye was purchased from Sigma; and finally, EMCV virus was provided by 
Digna Biotech. 
 
Cell culture 
HeLa cells (CCL-2), which are human epithelial cervix adenocarcinoma cells, were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). 
Cells were incubated in DMEM supplemented with 10% fetal bovine serum and 1% 
antibiotic (Penicillin-Streptomycin) (complete DMEM medium). 
 
Test item (IFN-α5) and serum samples 
IFN-α5 was provided by Sicor Biotech UAB (Vilnius, Lithuania). IFN-α5 was produced 
through recombinant DNA technology in E. Coli and a structural characterization and 
evaluation of physicochemical properties of purified IFN-α5 protein were carried out 
[8]. The original test item was used to obtain a stock solution (SS) of IFN-α5 at 1 x 108 
IU/mL in culture medium (complete DMEM medium). This SS was aliquoted and 
stored at -80 ºC until its use in the preparation of the standard curves and for the spiking 
of the serum samples.  
The serum was obtained from six Macaca fascicularis macaques at the animal care facility 
of the University of Navarra and also from ten healthy volunteers at the Clínica 
Universidad de Navarra (CUN) blood extraction service. Blood was collected in BD 
Vacutainer® SST extraction tubes with serum separator gel, maintained 1 hour at 
ambient temperature in a vertical position and centrifugated following the 
manufacturer's instructions. The obtained serum was aliquoted and stored at -80 ºC. 
Extraction of blood from the animals and volunteers was approved by the Animal 
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Experimentation Ethics Committee and Research Ethics Committee of the University of 
Navarra, respectively.  
The serum used for the spiking process, with the exception of that used in the study of 
the selectivity parameter, was a pool of blank macaque or human serum.  
 
Antiviral assay procedure 
The bioassay was conducted on a 96-well cell culture plate compatible with 
luminometry (opaque white plate with clear bottom) (figure 1). The inner 60 wells were 
only used due to the uneven response of the outer wells. The standards (standard curve), 
the controls (growth control and viral effect control) and the samples (blank and spiked, 
or the real samples of a study) were included in the plate, each in triplicate (figure 2). 
The growth control (nonvirus-treated HeLa cells) was used for evaluating the normal 
growth of the cells, and the viral effect control (HeLa cells treated with virus) was 
necessary in order to evaluate the viral cytopathic effect in the absence of IFN-α5. 
First, 50 µL of complete DMEM medium was added to the control wells (growth 
control and viral effect control wells). 50 µL of each point of the standard curve and 50 
µL of each sample (blank and spiked, or the real samples of a study) were then added to 
the corresponding wells. 
Next, 20,000 HeLa cells per well were seeded, adding 100 µL of 2 x 105 cell/mL cell 
suspension to all the wells of the plate. The plate was incubated in an incubator at 37ºC 
and with 5% CO2 for at least 12 hours. 
After that, an EMCV virus dilution was prepared in order to produce a complete 
cytopathic effect (in the viral effect control) starting with the stock concentration of the 
EMCV virus in complete DMEM medium (about 2 x 107 pfu/mL). The dilution was 
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agitated with a vortex and 50 µL were added to all the wells except to the growth 
control wells. Then, the plate was incubated in an incubator at 37ºC and with 5% CO2 
for 16 hours. 
Before proceeding to the plate washing and development process, the cells are observed 
in order to ensure that the cytopathic effect of the virus is complete. This is 
accomplished by observing the viral effect control wells under a microscope (x4, 
Eclipse TS100, Nikon), in which cell lysis should have occurred as a result of the viral 
effect, and by comparing the wells with the growth control wells in which the cells 
ought to be at confluence. Next, the luminescence reading was carried out using the 
Vialight® Plus kit following the manufacturer’s protocol. Briefly, the plate was removed 
from the incubator and left for 5 minutes at room temperature (RT). A vacuum pump 
was used to remove the medium from all the wells and they were washed with 200 µL 
of PBS with Ca2+ and Mg2+. Then, 100 µL of PBS with Ca2+ and Mg2+ and 50 µL of 
Cell Lysis Reagent were added to each well and left for 20 minutes at RT with orbital  
agitation. Finally, 100 µL of the ATP Monitoring Reagent was added to each well and 
after 2 minutes at RT, the luminescence was read using a luminometer (Mutimode 
detector DTX-800, Beckman Coulter).  
 
Quantification procedure 
The final step of the method was to calculate the IFN-α5 activity of each sample. The 
mean value of luminescence obtained for the three replicas corresponding to the viral 
effect control was subtracted from the values of luminescence obtained for each point 
and replica corresponding to the standard curve, thereby obtaining the corrected 
luminescence values of each point assayed.     
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Next, the mean value of the corrected luminescence values for each activity of IFN-α5 
of the standard curve analyzed in triplicate was obtained. Then a graphic representation 
was made of the standard curve (dispersion graph: IFN-α5 activity (IU/mL) on the x 
axis versus mean value of corrected luminescence (RLU: Relative Light Units) on the y 
axis).  
And finally, the mean value of luminescence obtained for the three replicas 
corresponding to the virus control was subtracted from the values of luminescence 
obtained for each blank and spiked sample and corresponding replicas. Then, the 
activities of IFN-α5 were calculated in each blank and spiked sample evaluated by 
means of extrapolation of each corrected luminescence in the equation obtained in the 
standard curve. 
 
Assay optimization 
In order to develop an adequate AVA, different aspects were optimized. The 
manufacturer´s protocol for the Vialight® Plus kit allows for the two reagents (Cell Lysis 
Reagent and ATP Monitoring Reagent) to be added directly to the culture well without the 
requirement of cell washing or medium removal. In order to evaluate the lack of sensitivity 
loss in our assay conditions, the influence of the culture medium and matrix (serum) on the 
reagents from the kit was studied. Therefore, cell viability was measured following the kit 
protocol on cells grown in culture medium or at different proportions of serum in culture 
medium. An evaluation was also carried out in order to determine the influence of the 
matrix on the accuracy and precision parameters of the standard curves, and the adequate 
quantification interval. Therefore, comparisons were made between standard curves 
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obtained with IFN-α5 in culture medium and IFN-α5 in different proportions of serum in 
culture medium. 
 
Assay validation   
Selectivity 
The capability of the bioassay to quantify IFN-α5 in the presence of other matrix (macaque 
Macaca fascicularis and human serum) components was evaluated. In order to do so, a 
study was carried out with serum obtained from five animals and ten volunteers. For each 
animal or volunteer, blank serum samples (basal) and serum samples spiked with two 
different IFN-α5 activities were compared. Each sample was analyzed in triplicate.  
The bioassay was considered to be selective if the responses of the basal serum samples 
were not higher than those obtained with the viral effect control taking an error of 30% 
into account. In addition, an increase in the signal of spiked serum samples for each 
individual should be observed when compared to the blank serum samples. The 
coefficients of variation (CV) and relative errors (RE) for each spike serum sample and 
individual must not be higher than the CV expected for the bioassay (30%).   
 
Standard curves 
Standard curves were prepared in different proportions of serum in the culture medium 
ranging from 0.7 to 25 IU/mL of IFN-α5. In order to obtain a large quantification range, 
different dilutions of serum with culture medium were prepared: 1/10, 1/100, 1/300, 
1/5000 and 1/10000 of macaque serum in complete DMEM medium; and 1/10 and 1/100 
of human serum in medium. An intermediate dilution of 41.66 IU/mL was obtained from 
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the SS in each of the aforementioned proportions of serum in complete DMEM 
medium. Each of these intermediate dilutions was used to make 3/5 serial dilutions in 
the plate, taking 75 µL from the previous well and adding 50 µL of the corresponding 
proportion of serum in complete DMEM medium. In this way, the activities 0.7, 1.2, 
1.9, 3.2, 5.4, 9, 15 and 25 IU/mL of IFN-α5 were obtained for each standard curve 
point, maintaining the desired proportion of serum in culture medium. The standard 
curves were performed according to the AVA procedure in triplicate on six different days. 
Precision and accuracy of the standard curves were studied. 
The acceptance criteria for the standard curves was to have a minimum of six points, an  
R2 ≥ 0.98, with a CV and a RE of the three replicates and on six different days (3 x 6 = 
18 replicates), ≤ 30%.    
 
Precision and accuracy 
The precision expresses the capability of an assay to provide closeness of agreement 
between results. Accuracy shows the capability of an assay to provide results that are as 
close as possible to the theoretical value. In order to assess these two parameters on the 
spiked serum samples, they were analyzed in the AVA on six different days. The activity 
corresponding to the spiked serum samples analyzed and the dilution used are described 
in table 1. The spiked samples are 100% serum. The acceptance criteria were that the 
CV and the RE of the three replicates, on six different days, must be ≤ 30% in at least 
75% of the spiked samples. In addition, the sum of the % of the CVs plus the % of the RE 
for the six repetitions made (3 x 6 = 18 replicates) must be ≤ 40%.  
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Robustness 
The test item batch and the development kit reagent batch may vary in subsequent studies 
using this quantification method. In order to evaluate the robustness of the AVA in these 
terms, a study was made with two batches of IFN-α5 and two batches of the reagents from 
the Vialight® Plus kit. 
Standard curves were obtained with each batch of IFN-α5. In addition, the same IFN-α5 
was used to obtain standard curves but processed with two batches of the reagents from the 
Vialight® Plus kit. For each IFN-α5 or kit batch change, each standard curve must comply 
with the repeatability and accuracy criteria established (CV ≤ 30%; RE ≤ 30%) when 
extrapolated within the other standard curve. 
 
Sample stability 
The stability of IFN-α5 in macaque and human serum in storage at -80 ºC was determined. 
For the macaque serum samples, an analysis was carried out on serum samples spiked with 
six activities within the quantification interval (12.5, 125, 500, 2000, 50000 and 200000 
IU/mL), at the following time intervals after been maintained at -80ºC: time 0, 24 and 
48 hours, one and two weeks. For the human serum samples, an analysis was carried out 
on serum samples spiked with two activities within the quantification interval (10 and 
2000 IU/mL), at time 0 and after 72 hours, 1 week, 1, 2, 3, 4, 5 and 6 months after having 
been frozen. A frozen blank serum sample was also analyzed for each time interval. For 
each stability condition, IFN- α5 levels versus time were plotted. It was assumed that IFN- 
α5 remained stable if a straight line was obtained in which the confidence interval of the 
slope included 0 with a p<0.05.  
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The stability of IFN-α5 in human serum (10 and 2000 IU/mL) after 1 and 3 consecutive 
freeze-thaw cycles, and after 2 hours at RT and on ice before its quantification, was also 
studied. As in the rest of the parameters studied, each sample was analyzed in triplicate. 
IFN-α5 was considered to be stable following 1 or 3 consecutive freeze-thaw cycles or 
after 2 hours at RT and on ice before its quantification if the mean of the activity levels 
measured for each condition was within the interval formed by the nominal value (activity 
value at which the sample was spiked: 10 or 2000 IU/mL), taking into account the assay 
error (RE ≤ 30%). 
Finally, the stability of the SS of IFN-α5 in culture medium (1 x 108 IU/mL) was also 
evaluated after approximately 1 month in storage at -80 ºC, comparing it with a SS 
prepared on the day of use. Standard curves were obtained with both SS on the same plate, 
and the mean luminescence values obtained with the IFN-α5 SS frozen for 1 month were 
plotted against the mean luminescence values obtained with the SS prepared at that 
moment. The IFN-α5 SS frozen at -80 ºC was considered to be stable if a line was obtained 
with a value of R2 ≥ 0.99 whose ordinate at the point of intersection includes 0, with a 
probability of 95%, and whose slope includes 1 with a probability of 95%. 
 
Quantification limit 
The lowest level of IFN-α5 that reached a good quantification, with adequate precision 
and accuracy values, was defined as the limit of quantification and it was included as 
the lowest level in the standard curve. 
 
Results 
Optimization 
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It was observed that the culture medium and the matrix (serum) interfere with the lysis 
reagent of the Vialight® Plus kit. A much lower response was observed in those wells in 
which the lysis reagent was added directly to the culture medium, the serum, or a mixture 
of both. Therefore, it was decided to introduce a washing step at the plate development 
stage in the manufacturer’s protocol.  
The serum interfered in the AVA, promoting cell growth which, in turn, gave rise to a 
different response between the IFN-α5 and the virus. It was observed that the greater the 
proportion of serum in the well, the greater the response, meaning the greater the cell 
growth. Inter-plate cell growth variability was also observed. Due to these observations, 
both the samples (blank, spiked or the real samples of a study) and the standard curve need 
to be tested in the same proportion of serum and culture medium, and also on the same 
plate. The results of this study suggest also that the lowest proportion of serum in complete 
DMEM medium at which the AVA must be validated is 1/10. It was confirmed that lower 
dilutions of serum in complete DMEM medium, for example 1/2 or 1/5, did not meet the 
validation established criteria. 
Finally, after evaluating different concentrations in order to determine the quantification 
interval (from 0.32 to 83.32 IU/mL), a range of 0.7 to 25 IU/mL of IFN-α5 was considered 
to be adequate because quantification of the analyte with good values of precision and 
accuracy was achieved. 
 
Selectivity 
The bioassay was confirmed to be selective, by demonstrating that the AVA was 
capable of quantifying IFN-α5 in the presence of other components in the serum of five 
different macaques and ten volunteers. The responses of the basal serum samples were 
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not higher than those obtained with the viral effect control taking the method error into 
account (table 2). In addition, the signal was observed to increase when comparing the 
blank serum samples with the spiked serum samples for each individual. After 
calculating the CV and RE for the results obtained for each spiked sample and all the 
individuals, this was ≤ 30% (tables 3-4). The noninfluence of each individual on the 
reproducibility of the results was therefore also demonstrated. 
 
Standard curves 
Standard curves were obtained with a quantification interval from 0.7 to 25 IU/mL for 
the different proportions of serum in culture medium (1/10, 1/100, 1/300, 1/5000 and 
1/10000 for macaque serum; 1/10 and 1/100 for human serum), with a minimum of six 
points and with a value for R2 ≥ 0.98 (figure 3); for the triplicate analysis, both CV and 
RE were ≤ 30% on six different days. Taking into account the dilution factor to be applied 
in the problem serum samples (1/10, 1/100, 1/300, 1/5000 and 1/10000), this 
quantification interval will allow samples to be quantified within an interval from 7 to 
250000 IU/mL in macaque serum, and from 7 to 2500 IU/mL in human serum.  
 
Precision and accuracy 
In the repeatability and intermediate precision study with serum samples spiked with IFN- 
α5, precise measurements were obtained, where 75% of the points gave a value of CV ≤ 
30% (table 5). In the within- and between-day accuracy studies, the measurements gave an 
RE ≤ 30% (table 6). In addition, the sum of the % of the CV plus the % of the RE in the 
six repetitions carried out was ≤ 40% (table 7). 
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Robustness 
The robustness of the bioassay was demonstrated by changing the IFN-α5 batch and the 
batch of reagents of the development kit (Vialight® Plus). The measurements complied 
with the established criteria of repeatability and accuracy (tables 8-9).  
 
Sample stability 
In all the conditions evaluated, IFN-α5 remained stable. IFN-α5 in macaque serum was 
stable at -80 ºC for a two week time interval, and up to 6 months in human serum, as the 
confidence interval of the slopes with a p=0.05 included 0 (tables 10-13). Moreover, IFN-
α5 was also stable in human serum after 1 and 3 consecutive freeze-thaw cycles and after 2 
hours at RT and on ice before its quantification. 
IFN-α5 SS was stable for 39 days frozen at -80 ºC given the fact that a line was obtained 
(y=0.9604x – 534.98) with R2 ≥ 0.99 whose ordinate at the point of intersection included 0 
(-1518.2413, 448.2736) with a probability of 95% and whose slope included 1 (0.8998, 
1.0209) with a probability of 95%. 
 
Discussion 
The regulatory agencies demand that the validation of the bioanalytical methods be 
developed according to the guidelines currently in force [9-11]. However, no specific 
guidelines regarding these particular bioassays exist. Furthermore, the available 
guidelines, where the acceptance criteria of the essential parameters to be studied are 
described, are being discussed because they focus more on chromatographic assays for 
small molecules. The increasing interest in macromolecular therapies (recombinant 
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proteins, cytokines, monoclonal antibodies, etc.) has highlighted the need for new 
different assays for quantifying these molecules. Over the past few years, many efforts 
have been made and many aspects have been discussed at different workshops and 
conferences in order to set up the minimum requirements for bioanalytical methods 
[12]. The approach and the validation criteria we selected for the AVA to quantify IFN-
α5 activity are based on current guidelines, and also on recent publications and reports 
regarding this topic, especially applicable to ligand-binding assays [13-16]. 
There are many cell/virus combinations that can be used to construct AVA. EMCV 
virus was selected because it is stable, has low pathogenicity for humans, and is 
sensitive to interferon [17]. Furthermore, the combination of the EMCV virus with 
HeLa cell line has shown high sensitivity and good dose-response relationship in 
different studies [18,19]. This, together with a very sensitive method at the point of 
termination of AVA used for evaluating cell viability (Vialight® Plus kit), capable of 
discriminating as few as ten cells, leads to the results showed in this work. Vialight® 
Plus kit is based upon the bioluminescent measurement of ATP in metabolically active 
cells. The washing step that has been included in the assay contributes to the elimination 
of the dead adherent cells that remain attached to the plastic bottom of the wells giving a 
low background in the viral effect control wells. This fact is important because high 
backgrounds may affect the slope of the dose response lines and therefore, adversely 
impact on the outcome of AVA [1]. Therefore, the novelty of the integration of AVA 
with the HeLa cells, EMCV and Vialight® Plus assay is highlighted, showing robust 
dose-response data in serum samples.  
This bioassay is not a ligand specific assay, but it allows the quantification of IFN-α5 
present in the samples through its activity. Antiviral efficacy was determined by 
measuring the ATP level in cells that were protected from the viral cytopathic effect by 
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the presence of IFN-α5. This is a very important aspect that the methods that are specific 
have to resolve, thereby needing a correlation between the product concentration measured 
and the biological response evaluated on a bioassay [14]. Although, it is not specific for 
IFN-α5, the AVA was confirmed as being selective because it demonstrated that it was 
capable of quantifying IFN-α5 activity in the presence of other components in the 
serum. The responses of the macaque and volunteers´ basal serum samples were not 
higher than those obtained with the viral effect control. These samples did not show any 
antiviral activity in our assay conditions. Only when the samples were spiked with IFN-
α5, antiviral activity was measured, and furthermore, with good precision and accuracy. 
The analysis of basal serum samples from five animals and ten volunteers, also 
demonstrated the noninfluence of each individual on the reproducibility of the results. 
Standard curves were obtained with a quantification interval from 0.7 to 25 IU/mL for 
the different selected proportions of serum in culture medium, allowing samples to be 
quantified within an interval from 7 to 250000 IU/mL in macaque serum, and from 7 to 
2500 IU/mL in human serum. This interval permits quantification from very low levels, 
necessary for human IFN-α5 pharmacokinetic profile, to very high levels that could be 
achieved in repeated dose toxicokinetic studies in animals. Taking into account the data 
of the antiviral activity per mg of protein and protein content of the IFN-α5 provided by 
the manufacturer, the bioassay was capable of measuring the activity of IFN-α5 in the 
range of pg/mL. This limit of detection is quite low and difficult to obtain with other 
analytical methods.   
Assay precision and accuracy has been set at 30% for both inter- and intra-assay 
variations (within and between days). This error percentage is higher than those 
permitted in the guidelines [9,11]. For the ligand-binding assays, the acceptance criteria 
for calibration standards (standard curve) and spiked samples is that a minimum of 75% 
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and 67% of the samples, respectively, should have an error no greater than 20%, or 25% 
for the low and high points [15]. In this type of biological activity assays, it is usual to 
have larger variations, more than with chromatographic or ligand-binding assays, due to 
inherent biological sources of variation that are not completely controllable (cell growth, 
virus activity, larger assay times, etc.). Our validation data has shown that if these 
variations are known, assumed and reflected in the assay performance acceptance criteria, 
the assay can be appropriate for its intended use. Recent publications regarding 
bioanalytical method validation for macromolecules and biomarkers are also supporting 
the idea that the levels of precision and accuracy do not necessarily have to be linked to 
any particular threshold, but should be scientifically justified so that the variability and 
accuracy of the assay are acceptable for its purpose [14].  
Another advantage is that the same bioassay with the same procedure has shown to be 
valid for both macaque and human serum. Furthermore, the bioassay has demonstrated 
the stability of the IFN-α5 in macaque and human serum stored at -80 ºC, thereby 
allowing sample conservation without loss of its properties for several days or months. 
It was assumed that a 15-day interval was enough for measuring all the samples of the 
preclinical studies. However, for human samples, stability for up to 6 months was 
studied because the patient recruitment for clinical trials is not always easy and can 
often involve long time periods. This stability allows measuring human serum samples 
extracted during a 6 months period at the same time. Furthermore, the bioassay showed 
the stability of IFN-α5 in human serum after 1 and 3 consecutive freeze-thaw cycles, a 
great advantage for repeating the measurements of these valuable human samples.  
In the regulatory field, these results can also contribute to the improvement of the 
specific requirements and recommendations established for different assays and 
validation procedures by the regulatory bodies. This work also supports the idea of 
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fitting the validation procedures and requirements for the different assays and purposes. 
In conclusion, this study presents novel integration of an AVA with EMCV in HeLa cells 
with Vialight® Plus assay. In view of the results obtained, this AVA is valid for 
quantifying IFN-α5 activity in macaque Macaca fascicularis and human serum in order to 
generate reliable pharmacokinetic and toxicokinetic data. The bioassay has been 
successfully applied to the study of the pharmacokinetic profile of IFN-α5 after 
subcutaneous and intravenous administration to macaques and to a 31-day repeated dose 
toxicokinetic study after subcutaneous administration of IFN-α5 to macaques. 
Following the positive assessment of the regulatory bodies, the bioassay is also currently 
being applied to a clinical trial in treatment-experienced patients with genotype-1 
chronic hepatitis C. 
 
Executive summary 
• Assay: A novel integration of an antiviral assay (AVA) against the cytopathic effect of the 
encephalomyocarditis virus in HeLa cells with a very sensitive method for AVA 
processing, Vialight® Plus assay, is presented for IFN-α5 activity quantification. 
• This bioassay is not a ligand specific assay, but it allows the quantification of IFN-α5 
present in the samples through its activity. 
• Assay validation: The validated bioassay meets suitable acceptance criteria for these 
types of biological assays. 
• Selectivity: The AVA was confirmed as being selective because it demonstrated that it 
was capable of quantifying IFN-α5 activity in the presence of other components in the 
serum. 
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• Standard curves: Standard curves were obtained with a quantification interval from 0.7 
to 25 IU/mL for the different selected proportions of serum in culture medium, allowing 
samples to be quantified within an interval from 7 to 250000 IU/mL in macaque serum, 
and from 7 to 2500 IU/mL in human serum. 
• Sensitivity: The bioassay was capable of measuring the activity of IFN-α5 in the range 
of pg/mL showing a high sensitivity. 
• Precision and accuracy: Assay precision and accuracy has been set at 30% for both 
inter- and intra-assay variations (within and between days). 
• Minimum required dilution:  the minimum required dilution for samples at which the 
AVA must be performed is 1/10 (serum in complete DMEM medium). Samples that need 
additional dilution should be diluted with complete DMEM medium and in all cases, the 
standard curve need to be tested in the same proportion of serum and culture medium of 
the samples. 
• Regulatory acceptance: In the regulatory field, these results can contribute to the 
improvement of the specific requirements and recommendations established for 
different assays and validation procedures by the regulatory bodies. 
 
Future perspective 
Focus our research on bioanalytical assay development for therapeutic proteins. 
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Tables 
 
Table1. Spiked serum samples analyzed for IFN-α5 activity  
Dilution used IFN-α5 activities (IU/mL) 
Macaque serum 
1/10 12.5, 20, 50, 100, 200 
1/100 125, 200, 500, 1000, 2000 
1/300 375, 600, 1500, 3000, 6000 
1/5000 6250, 10000, 25000, 50000, 100000 
1/10000 12500, 20000, 50000, 100000, 200000 
Human serum 
1/10 20, 51, 102, 152, 203 
1/100 185, 406, 841, 1219, 1523 
 
 
 
 
Table 2. Selectivity: Mean luminescence signals (RLUs) obtained for the basal serum from each 
animal and each volunteer  
Macaque serum      
Animal  1 2 3 4 5      
Mean basal serum signal 3033 2087 1199 2563 1122      
Mean viral effect control signal  3019 2627 1487 1944 1181      
Human serum 
Volunteer 1 2 3 4 5 6 7 8 9 10 
Mean basal serum signal 986 620 613 525 449 1193 868 760 886 881
Mean viral effect control signal 1098 1236 
 
Table 3. Precision and accuracy of each macaque for the samples spiked for selectivity  
Volunteer 1 2 3 4 5 
Spiked (IU/mL serum) 1.25 20 1.25 20 1.25 20 1.25 20 1.25 20 
Measured (IU/mL serum) 1.48 22.75 1.46 16.19 1.41 25.57 1.03 17.19 1.05 15.11 
Precision (%CV) 20.29 10.10 10.14 12.63 22.37 11.27 2.81 7.97 15.33 9.76 
Accuracy (%RE) 18.13 13.73 17.07 19.07 12.53 27.86 17.87 14.05 16.00 24.43 
 
 
Table 4. Precision and accuracy of each volunteer for the samples spiked for selectivity  
Volunteer 1 2 3 4 5 6 7 8 9 10 
Spiked (IU/mL serum) 20 52 102 152 203 20 52 102 152 203 
Measured (IU/mL serum) 25.05 58.94 98.98 192.20 220.74 21.62 45.53 116.72 121.29 176.06
Precision (%CV) 21.56 8.63 6.06 27.36 23.88 20.94 29.02 9.17 27.23 15.85 
Accuracy (%RE) 23.28 16.03 2.58 26.12 8.63 6.42 10.37 14.88 20.41 13.36 
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Table 5. Repeatability and intermediate precision (CV) of the AVA for IFN-α5* 
Spiked samples 
activity (IU/mL) Dilution used 
Repeatability (%) 
(Within day) 
Intermediate precision (%) 
(Between days) 
Macaque serum 
12.5 6.95 25.68 
20 12.63 27.32 
50 10.91 24.90 
100 16.92 22.57 
200 
1/10 
28.92 28.34 
125 10.22 11.71 
200 7.12 17.24 
500 3.19 18.70 
1000 23.21 28.78 
2000 
1/100 
17.90 11.47 
375 6.17 8.08 
600 20.02 14.82 
1500 18.25 25.87 
3000 14.40 17.77 
6000 
1/300 
16.95 28.79 
6250 4.71 13.20 
10000 9.09 15.58 
25000 10.55 31.46 
50000 24.61 30.12 
100000 
1/5000 
28.00 21.52 
12500 14.41 13.57 
20000 19.68 18.61 
50000 16.33 22.48 
100000 16.21 32.34 
200000 
1/10000 
10.87 29.87 
Human serum 
20 21.56 30.96 
51 8.63 26.20 
102 6.06 21.44 
152 27.36 24.16 
203 
1/10 
23.88 18.94 
185 13.65 77.40 
406 9.53 24.23 
841 15.57 20.79 
1219 14.29 19.82 
1523 
1/100 
11.55 14.19 
*Samples were analyzed in triplicate with five different activities of IFN-α5 after different dilutions 
(within day); this was also done on six different days (between days)  
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Table 6. Within and between days accuracy (RE) of the AVA for IFN-α5* 
Spiked samples 
activity (IU/mL) Dilution used 
Accuracy (%) 
(Within day) 
Accuracy (%) 
(Between days) 
Macaque serum 
12.5 11.26 6.48 
20 24.43 8.38 
50 24.90 11.93 
100 16.30 15.99 
200 
1/10 
13.99 1.66 
125 3.10 3.67 
200 4.60 8.07 
500 21.64 1.86 
1000 18.30 5.04 
2000 
1/100 
13.56 15.47 
375 25.02 20.12 
600 28.66 25.23 
1500 20.08 8.89 
3000 0.95 2.91 
6000 
1/300 
14.92 1.90 
6250 4.71 10.99 
10000 9.09 23.44 
25000 10.55 0.76 
50000 24.61 2.82 
100000 
1/5000 
28.00 17.57 
12500 17.31 7.80 
20000 17.39 8.86 
50000 29.13 5.19 
100000 19.17 6.91 
200000 
1/10000 
7.55 1.33 
Human serum 
20 23.28 5.60 
51 16.03 11.59 
102 2.58 19.75 
152 26.12 0.93 
203 
1/10 
8.63 4.42 
185 13.10 19.60 
406 11.94 11.49 
841 8.88 2.41 
1219 14.98 1.85 
1523 
1/100 
22.80 1.32 
*Samples were analyzed in triplicate with five different activities of IFN-α5 after 
 different dilutions (within day); this was also done on six different days (between days)  
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Table 7. Sum of the CV and RE of the AVA for IFN-α5 on the six repetitions performed 
Spiked samples 
activity (IU/mL) Dilution used CV+ RE (%) 
Macaque serum 
12.5 32.16 
20 35.71 
50 36.84 
100 38.57 
200 
1/10 
29.99 
125 15.38 
200 25.31 
500 20.56 
1000 33.82 
2000 
1/100 
26.94 
375 28.19 
600 40.05 
1500 34.76 
3000 20.69 
6000 
1/300 
30.69 
6250 24.19 
10000 39.03 
25000 32.23 
50000 32.94 
100000 
1/5000 
39.10 
12500 21.37 
20000 27.47 
50000 27.67 
100000 39.25 
200000 
1/10000 
31.20 
Human serum 
20 36.56 
51 37.79 
102 41.19 
152 25.09 
203 
1/10 
23.36 
185 97.00 
406 35.72 
841 23.19 
1219 21.68 
1523 
1/100 
15.52 
 
 
 
 
Table 8. Repeatability and within-day accuracy obtained with two different batches of IFN α5 (1 and 2), extrapolated in the curves obtained with both batches, 
respectively 
 Standard curve 
Batch 1 
Standard curve 
Batch 2 
Standard curve 
Batch 1 
Standard curve 
Batch 2 
Standard curve 
Batch 1 
Standard curve 
Batch 2 
 Activity measured (IU/mL) Repeatability (CV; %) Within-day accuracy (RE; %) 
Activity (IU/mL) Batch 1 Batch 2 Batch 2 Batch 1 Batch 1 Batch 2 Batch 2 Batch 1 Batch 1 Batch 2 Batch 2 Batch 1 
25.91 38.27 36.55 24.70 
42.59 20.58 19.61 40.69 25 
22.99 17.52 16.68 21.91 
34.67 44.00 44.19 34.82 21.98 1.84 2.89 16.40 
13.15 25.81 24.61 12.50 
13.84 19.45 18.52 13.16 15 
21.08 14.03 13.34 20.08 
27.41 29.84 29.96 27.53 6.82 31.77 25.50 1.65 
7.59 11.36 10.80 7.19 
8.77 9.00 8.54 8.32 9 
10.84 10.43 9.91 10.29 
18.16 11.62 11.67 18.23 0.69 14.04 8.31 4.41 
4.12 6.87 6.51 3.89 
4.05 4.57 4.33 3.83 5.4 
6.08 4.59 4.34 5.76 
24.32 24.73 24.83 24.43 12.07 1.09 6.31 16.76 
2.37 3.16 2.99 2.24 
2.68 2.72 2.56 2.53 3.2 
2.62 2.86 2.70 2.47 
6.36 7.87 7.90 6.39 21.09 10.12 15.09 25.49 
-- -- -- -- 
-- -- -- -- 1.9 
-- -- -- -- 
-- -- -- -- -- -- -- -- 
1.18 1.12 1.05 1.11 
1.15 1.07 1.01 1.09 1.2 
0.97 1.19 1.12 0.91 
10.62 5.26 5.29 10.67 5.72 3.21 8.92 11.29 
0.90 0.90 0.84 0.85 
0.85 0.86 0.81 0.80 0.7 
0.94 0.86 0.81 0.89 
5.05 2.20 2.21 5.07 28.27 25.12 17.62 20.58 
       -- Point ruled out for non-compliance with the established criterion. 
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Table 9. Repeatability and within-day accuracy of the standard curves obtained with two different batches of the reagents of the development kit (Vialight® 
Plus) (Batch 1 and 2), extrapolated in the curves obtained with both batches, respectively 
 Standard curve 
Batch 1 
Standard curve 
Batch 2 
Standard curve 
Batch 1 
Standard curve 
Batch 2 
Standard curve 
Batch 1 
Standard curve 
Batch 2 
 Activity measured (IU/mL) Repeatability (CV; %) Within-day accuracy (RE; %) 
Activity (IU/mL) Batch 1 Batch 2 Batch 2 Batch 1 Batch 1 Batch 2 Batch 2 Batch 1 Batch 1 Batch 2 Batch 2 Batch 1 
22.31 28.03 15.46 18.92 
25.42 48.66 17.35 30.87 25 
32.44 42.52 21.55 27.39 
19.42 26.66 17.20 23.88 6.89 58.95 27.52 2.91 
-- -- 17.23 16.16 
-- -- 15.70 17.77 15 
-- -- 16.84 23.29 
-- -- 4.79 19.62 -- -- 10.60 27.15 
12.05 10.26 8.95 7.76 
9.79 9.63 7.45 7.34 9 
10.04 10.45 7.61 7.89 
11.64 4.24 10.29 3.77 18.06 12.40 11.09 14.85 
3.72 5.63 -- -- 
5.26 4.10 -- -- 5.4 
4.81 4.29 -- -- 
17.28 17.85 -- -- 14.85 13.40 -- -- 
-- -- -- -- 
-- -- -- -- 3.2 
-- -- -- -- 
-- -- -- -- -- -- -- -- 
1.52 1.58 1.43 1.47 
1.55 1.55 1.45 1.45 1.9 
1.55 1.57 1.45 1.47 
1.10 1.02 0.98 0.91 20.65 19.56 25.64 24.74 
1.21 1.18 1.17 1.14 
1.09 1.10 1.06 1.07 1.2 
1.06 1.16 1.04 1.12 
7.19 3.67 6.37 3.26 3.92 1.77 6.67 4.81 
0.92 0.94 0.91 0.93 
0.85 0.92 0.86 0.91 0.7 
0.87 0.88 0.87 0.88 
3.79 3.31 3.36 2.94 25.70 30.32 25.51 29.60 
         -- Point ruled out for non-compliance with the established criterion. 
 Table 10. Activity measured in the macaque stability study samples 
 Activity measured (IU/mL) 
Activity 
(IU/mL) 0 h 24 h 48 h 
168 h 
(1 week) 
336 h 
(2 weeks) 
173129.56 -- 103607.56  184047.71 
209932.59 115438.93 157388.16  184624.54 200000 
171647.07 147350.20 96495.67  182374.28 
Mean 184903.07 131394.57 130497.86  183682.18 
CV (%) 11.73 17.17 25.51  0.64 
55156.23 49965.57 33590.89  39139.64 
44818.06 44744.63 34963.63  57876.12 50000 
35066.98 29317.50 --  38902.41 
Mean 45013.75 41342.57 34277.26  45306.06 
CV (%) 22.32 25.97 2.83  24.03 
2566.45 1559.47 1645.25 1085.80 1962.31 
2439.49 1587.25 -- 1404.52 2250.15 2000 
1807.47 1430.33 1520.45 1580.13 2073.80 
Mean 2271.14 1525.68 1582.85 1356.82 2095.42 
CV (%) 17.90 5.49 5.58 18.47 6.93 
403.61 293.68 597.20 440.11 627.38 
378.72 724.83 648.51 322.50 539.78 500 
393.06 335.48 549.88 344.01 470.56 
Mean 391.80 451.33 598.53 368.87 545.91 
CV (%) 3.19 52.68 8.24 16.98 14.40 
114.13 107.24 132.56 149.60 151.51 
133.02 110.27 151.26 157.04 167.56 125 
139.49 110.50 119.41 207.78 138.94 
Mean 128.88 109.34 134.41 171.47 152.67 
CV (%) 10.22 1.66 11.91 18.46 9.40 
6.22 14.44 14.84 10.87  
7.48 12.04 16.34 9.85  12.5 
6.08 11.26 14.08 8.05  
Mean 6.59 12.58 15.09 9.59  
CV (%) 11.73 13.18 7.63 14.90  
--Point ruled out for non-compliance with the established criterion 
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Table 11. Activity measured in the human samples spiked with 10 IU/mL of IFN α5 
 
Activity measured (IU/mL) 
Theoretic 
activity 
(IU/mL) 
Day 0 1 week
1 
month   
(30 
days) 
2-3 
months   
(79 
days) 
4 
months  
(121 
days) 
5 
months 
(143 
days) 
6 
months 
(185 
days) 
10.53 20.02 11.79 11.54 11.54 7.56 6.79 
10.64 9.48 12.54 12.53 13.04 7.94 6.12 10 
11.33 9.60 12.69 11.59 12.31 8.13 7.82 
Mean 10.83 13.03 12.34 11.89 12.30 7.88 6.91 
CV (%) 4.00 46.43 3.92 4.69 6.10 3.68 12.39 
 
 
 
 
 
 
 
 
 
Table 12. Activity measured in the human samples spiked with 2000 IU/mL of IFN α5 
--Point ruled out for non-compliance with the established criterion 
Activity measured (IU/mL) 
Theoretic 
activity 
(IU/mL) 
Day 0 3 days 
1 month
 (30 
days) 
2 
months   
(63 
days) 
3 
months   
(100 
days) 
4 
months 
(121 
days) 
5 
months 
(149 
days) 
6 
months 
(189 
days) 
2717.55 2252.97 1886.87 2123.45 2731.80 3594.61 2367.43 3302.14
2751.52 2376.61 2388.49 1769.59 2713.92 3531.00 2627.98 3435.502000 
-- 1782.24 2264.53 2083.63 2580.57 3696.67 2348.61 3025.31
Mean 2734.54 2137.27 2179.96 1992.22 2675.43 3607.43 2448.01 3254.32
CV (%) 0.88 14.67 11.99 9.73 3.09 2.32 6.38 6.43 
 
Table 13. IFN-α5 stability in macaque and human serum samples stored at -80 ºC 
Spiked 
sample 
activity 
(IU/mL) 
Dilution 
used Line equation Probability
Confidence interval 
for the slope 
Stable 
up to 
(days) 
Nº of 
time 
points 
studied
Macaque serum 
12.5 1/10 y=0.0045x + 10.757 0.9924 -0.1496, 0.1503 15 5 
125 1/100 y=0.1148x + 126.13 0.2110 -0.1156, 0.3452 15 5 
500 1/100 y=0.1738x + 451.26 0.6907 -1.0880, 1.4356 15 5 
2000 1/100 y=0.3499x + 1726.1 0.8430 -4.8124, 5.5121 15 5 
50000 1/5000 y=12.601x + 40200 0.6139 -79.0156, 104.2185 15 5 
200000 1/10000 y=92.042x + 148231 0.5302 -434.2023, 618.2869 15 5 
Human serum 
10 1/10 y=-0.0251x + 12.763 0.0517 -0.0504, 0.0003 185 7 
2000 1/100 y=4.7147x + 2242.6 0.1327 -1.9203, 11.3497 189 8 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
1. Adding standards, controls and samples (blank, spiked or problem) at the desired dilution to the 
96 well plate 
 
2. Seeding the cells 
 
3. Incubation at least 12h 
 
4. Inoculation with the virus 
 
5. Incubation between 15-18h 
 
6. Developing the plate (Vialight® Plus kit) 
 
7. Measuring the luminescence 
 
8. Data processing, evaluation and interpretation 
Figure 1. Flow chart for the performance of the AVA 
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Figure 2. 96 well plate design (ST: standards; VEC: virus effect control; GC: growth control; BS: 
blank sample; SS: spiked sample; PS: problem sample of a study) 
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Figure 3. Examples of standard curves (luminescence vs. activity) obtained at a dilution of A)1/10, 
B)1/100, C)1/300 and D)1/10000 in macaque serum; and E)1/10 and F)1/100 in human serum 
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